NEW YORK, April 19, 2017 /PRNewswire/ --
Stock-Callers.com takes a closer look at four major players in the Drug Manufacturers space to see how they have fared over the past trading sessions. Under assessment this morning are: Impax Laboratories Inc. (NASDAQ: IPXL), Sanofi (NYSE: SNY), Heron Therapeutics Inc. (NASDAQ: HRTX), and Alimera Sciences Inc. (NASDAQ: ALIM). These pharmaceutical companies are engaged in the research, development, marketing, and distribution of drugs that are used for nearly every therapeutic need. Learn more about these stocks by downloading their free report at:
On Tuesday, shares in Hayward, California headquartered Impax Laboratories Inc. recorded a trading volume of 1.80 million shares. The stock ended the session 2.31% lower at $12.70. The Company's shares have surged 35.11% in the last one month. The stock is trading 6.46% above its 50-day moving average. Moreover, shares of Impax Labs, which develops, manufactures, and markets bioequivalent pharmaceutical products, have a Relative Strength Index (RSI) of 52.21.
On April 06th, 2017, Impax Labs announced that it will release its Q1 2017 financial results on Wednesday, May 10th, 2017, prior to the open of the US financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. ET on the same day. The financial results and live webcast will be accessible under the Investor Relations section of the Company's website. The free research report on IPXL is available at:
Paris, France headquartered Sanofi's stock closed the day 2.37% lower at $44.45. A total trading volume of 1.69 million shares was traded, which was above their three months average volume of 1.46 million shares. The Company's shares have advanced 0.34% in the past month, 8.52% in the previous three months, and 9.92% since the start of this year. The stock is trading 1.47% and 8.75% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Sanofi, which researches, develops, manufactures, and markets therapeutic solutions, have an RSI of 45.92.
On April 03rd, 2017, Sanofi announced the launch of ACT® Kids Toothpaste, a new anti-cavity fluoride toothpaste that is specially developed for kids two years of age and older. In addition to the toothpaste, the ACT Kids line includes anti-cavity rinses that can be used after brushing by kids six years of age and older for the optimal oral care routine.
On April 07th, 2017, research firm HSBC Securities downgraded the Company's stock rating from 'Hold' to 'Reduce'. The complimentary report on SNY can be downloaded at:
Shares in Redwood City, California headquartered Heron Therapeutics Inc. recorded a trading volume of 554,739 shares. The stock ended yesterday's trading session 0.99% higher at $15.30. The Company's shares have advanced 6.99% in the past month, 19.07% in the previous three months, and 16.79% on an YTD basis. The stock is trading above its 50-day moving average by 7.25%. Furthermore, shares of Heron Therapeutics, which develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the US, have an RSI of 59.19. Visit us today and download our complete research report on HRTX for free at:
Alpharetta, Georgia headquartered Alimera Sciences Inc.'s stock finished Tuesday's session 1.44% lower at $1.37, with a total trading volume of 126,474 shares. The Company's shares have advanced 13.22% over the previous three months and 26.85% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.12% and 1.46%, respectively. Additionally, shares of Alimera Sciences, which engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the US and internationally, have an RSI of 46.39. Get free access to your technical report on ALIM at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA